Tag:
oritavancin
Latest Headlines
Latest Headlines
Targanta cuts jobs following FDA rejection
Targanta Therapeutics has decided to pull out the axe following the FDA's rejection of oritavancin, the company's experimental antibiotic for complicated skin and skin structure infections (cSSSI).
Targanta shares need antibiotics
Another company that is taking a hit in the wallet following bad trial news is Targanta Therapeutics. Shares in the company fell 43.6 percent yesterday afternoon and hit a 52-week low earlier in the
